O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+2.22%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.05B
AUM Growth
+$5.05B
(-3.3%)
Cap. Flow
-$81.2M
Cap. Flow
% of AUM
-1.61%
Top 10 Holdings %
Top 10 Hldgs %
35.6%
Holding
132
New
17
Increased
26
Reduced
29
Closed
15
Top Buys
| 1 |
Enliven Therapeutics
ELVN
|
$173M |
| 2 |
Biogen
BIIB
|
$68.6M |
| 3 |
Eli Lilly
LLY
|
$63.9M |
| 4 |
Baxter International
BAX
|
$63.4M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$60M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$117M |
| 2 |
Pfizer
PFE
|
$71.4M |
| 3 |
Natera
NTRA
|
$54M |
| 4 |
UnitedHealth
UNH
|
$49.4M |
| 5 |
89bio
ETNB
|
$46.6M |
Sector Composition
| 1 | Healthcare | 97.56% |
| 2 | Industrials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
GH Research
GHRS
$870M
| $13.3M | 0.26% |
1,659,015
+36,955
| +2% | +$295K |
|
77
Amicus Therapeutics
FOLD
$2.42B
| $13M | 0.25% |
1,171,000
+655,000
| +127% | +$7.26M |
|
78
ALX Oncology
ALXO
$54.6M
| $13M | 0.25% |
2,871,000
| – | – |
|
|
FUSN
79
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $11.8M | 0.23% |
3,122,770
-102,000
| -3% | -$385K |
|
|
IMA
80
ImageneBio, Inc. Common Stock
IMA
$153M
| $11M | 0.22% |
3,186,166
+252,225
| +9% | +$870K |
|
81
GoodRx Holdings
GDRX
$1.49B
| $10.6M | 0.21% |
1,700,000
+1,312,433
| +339% | +$8.2M |
|
82
Vera Therapeutics
VERA
$1.47B
| $10.6M | 0.21% |
+1,362,400
| New | +$10.6M |
|
83
BioAtla
BCAB
$28.7M
| $10.3M | 0.2% |
3,861,000
+3,528,628
| +1,062% | +$9.46M |
|
84
Passage Bio
PASG
$22.7M
| $8.55M | 0.17% |
8,931,999
| – | – |
|
85
Galecto
GLTO
$3.93M
| $8.14M | 0.16% |
4,090,937
| – | – |
|
86
Oric Pharmaceuticals
ORIC
$1.03B
| $7.83M | 0.15% |
1,374,468
-233,100
| -15% | -$1.33M |
|
87
Protagonist Therapeutics
PTGX
$3.62B
| $6.92M | 0.14% |
+301,000
| New | +$6.92M |
|
|
LSB
88
LakeShore Biopharma
LSB
$34.9M
| $6.88M | 0.14% |
+4,298,464
| New | +$6.88M |
|
89
Verastem
VSTM
$585M
| $6.85M | 0.13% |
16,503,237
| – | – |
|
90
Immatics
IMTX
$662M
| $6.54M | 0.13% |
+947,248
| New | +$6.54M |
|
91
Invivyd
IVVD
$218M
| $6.32M | 0.12% |
5,270,400
| – | – |
|
92
Corvus Pharmaceuticals
CRVS
$419M
| $6.32M | 0.12% |
6,943,654
| – | – |
|
93
Cullinan Oncology
CGEM
$456M
| $6.19M | 0.12% |
605,387
-31,900
| -5% | -$326K |
|
94
Intellia Therapeutics
NTLA
$1.26B
| $6.14M | 0.12% |
+164,627
| New | +$6.14M |
|
|
MREO
95
Mereo BioPharma
MREO
$275M
| $5.48M | 0.11% |
7,747,891
-2,857,631
| -27% | -$2.02M |
|
96
X4 Pharmaceuticals
XFOR
$70M
| $5.06M | 0.1% |
5,817,726
| – | – |
|
|
VIGL
97
DELISTED
Vigil Neuroscience
VIGL
| $4.39M | 0.09% |
448,891
| – | – |
|
98
Scholar Rock
SRRK
$3.3B
| $4.12M | 0.08% |
515,000
-364,003
| -41% | -$2.91M |
|
99
NextCure
NXTC
$13.3M
| $4.01M | 0.08% |
2,711,013
| – | – |
|
100
Synlogic
SYBX
$17.4M
| $3.81M | 0.07% |
6,029,995
| – | – |
|